Photo by atikahakhtar from unsplash
Bullous pemphigoid (BP) has been associated with dipeptidyl peptidase‐4 inhibitors (DPP4i). Clinical features, outcomes, and risk of BP for new DPP4i (linagliptin, saxagliptin, and alopgliptin) are not well established. Comparison… Click to show full abstract
Bullous pemphigoid (BP) has been associated with dipeptidyl peptidase‐4 inhibitors (DPP4i). Clinical features, outcomes, and risk of BP for new DPP4i (linagliptin, saxagliptin, and alopgliptin) are not well established. Comparison of risk of BP appearance for DPP4i and other oral antidiabetic drugs (OADs) such as sodium glucose cotransporter 2 inhibitors has not been studied to date.
Keywords:
peptidase inhibitors;
associated dipeptidyl;
pemphigoid associated;
bullous pemphigoid;
dipeptidyl peptidase
Journal Title: International Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!